# Exploring Clinical Trials for Peptides in Anxiety Disorders

Canonical source: https://retacompare.com/research/clinical-trial-landscape-for-peptides-in-anxiety-disorders

Peptides for Disease — Clinical Trials · 2026-05-03


    Current clinical trials investigating peptides for anxiety disorders include Selank, which has shown promise as an anxiolytic. However, most peptides discussed in the biohacker community lack FDA approval for these indications, highlighting the need for caution and further research.

 The big picture

Anxiety disorders represent a significant public health concern, affecting millions of individuals worldwide. Traditional treatments often include psychotherapy and pharmacotherapy, such as selective serotonin reuptake inhibitors (SSRIs) and benzodiazepines. However, the search for alternative therapies has led to interest in peptides, which are short chains of amino acids that can influence various biological processes. While some peptides are being studied for their potential anxiolytic properties, many remain unapproved by regulatory bodies, particularly in the United States. Understanding the current clinical trial landscape for these peptides is essential for clinicians and researchers alike. For broader context, see the broader research library and our peptide stacking guide.

 What the clinical evidence shows

Among the peptides investigated for anxiety disorders, Selank has emerged as a notable candidate. Registered in Russia as an anxiolytic, Selank has been reported to exhibit anxiolytic effects in controlled studies. Research indicates that it may modulate neurotransmitter systems, potentially leading to reduced anxiety symptoms. Additionally, Semax, another peptide with neuroprotective properties, is being explored for its effects on cognitive function and mood, although its primary focus is not specifically anxiety disorders. Other peptides, such as BPC-157, have been discussed in anecdotal contexts regarding their calming effects, but controlled clinical trial data supporting their efficacy in anxiety is lacking.

 What the community reports anecdotally

Anecdotal reports from the biohacker community suggest that various peptides, including BPC-157 and TB-500, are being used for anxiety management. Users report subjective improvements in mood and reductions in anxiety symptoms when using these peptides, often sharing their experiences in forums and podcasts. However, it is crucial to note that these self-reported benefits have not been substantiated by rigorous clinical trials. The lack of controlled studies means that these claims should be approached with caution, as anecdotal evidence does not equate to clinical efficacy.

 Key points at a glance

Selank is registered in Russia as an anxiolytic and has shown promising clinical signals.

Semax is under investigation for potential cognitive and mood-enhancing effects.

BPC-157 and other peptides are commonly discussed in biohacker circles but lack FDA approval.

Anecdotal reports from users highlight subjective benefits, but no controlled trials confirm these claims.

Many peptides discussed are not FDA-approved for anxiety disorders or any indication.

 Safety and what to watch for

The use of peptides, particularly those not approved by the FDA, carries inherent risks. Side effects can vary widely depending on the peptide and individual response. Without regulatory oversight, the purity and dosage of these substances can also be questionable, potentially leading to adverse effects. Clinicians should be aware of the potential for off-label use and the importance of discussing the risks associated with unregulated peptides with patients.

 Open questions

Despite the interest in peptides for anxiety disorders, significant gaps in research remain. Future studies are needed to establish the safety, efficacy, and mechanisms of action of these peptides. Regulatory uncertainty also persists, particularly in the United States, where many peptides are not approved for any indications. Understanding the long-term effects and potential interactions of these compounds will be crucial as research progresses.

 Bottom line

While peptides like Selank show promise in the treatment of anxiety disorders, most are not FDA-approved, and anecdotal reports should not replace clinical evidence. Ongoing research is essential to elucidate their role in anxiety management.

 This article is research-only educational content and is not medical advice. Many of the peptides discussed are not FDA-approved for Anxiety Disorders or any indication. Do not start or change therapy without consulting a qualified clinician.

## Sources